Sun Pharmaceutical Industries and Philogen SpA have entered into a licensing agreement for commercialising Philogen’s specialty cancer product, Nidlegy (Daromun) in Europe, Australia, and New Zealand. Nidlegy, currently in advanced Phase III clinical trials, is a new immunotherapy product being developed by Philogen to treat melanoma and non-melanoma skin cancers. Under the terms of the agreement, Sun will have exclusive rights to commercialise Nidlegy for indications of skin cancers in Europe, Australia, and New Zealand. Sun Pharma will be responsible for commercialisation activities, it said, and two partner companies would equally share post-commercialisation economics, the company added. Philogen will retain intellectual property rights for Nidlegy for other territories and indications other than skin cancers.

Source: The Hindu May 30, 2023 20:43 UTC